Literature DB >> 7540727

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

J Levitskaya1, M Coram, V Levitsky, S Imreh, P M Steigerwald-Mullen, G Klein, M G Kurilla, M G Masucci.   

Abstract

The Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers, and is the only viral protein regularly detected in all malignancies associated with EBV. Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated. Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen A11-restricted CTL epitope, amino acids 416-424 of the EBNA4 protein, inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly-Ala repetitive sequence, we demonstrate that the Gly-Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly-Ala repeats downstream of the 416-424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540727     DOI: 10.1038/375685a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  230 in total

1.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.

Authors:  B T Tan; L Wu; A J Berk
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus.

Authors:  D F Ceccarelli; L Frappier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 5.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

6.  Expression of two related viral early genes in Epstein-Barr virus-associated tumors.

Authors:  S A Xue; Q L Lu; R Poulsom; L Karran; M D Jones; B E Griffin
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.

Authors:  M A Lee; M E Diamond; J L Yates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 9.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

10.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.